Ziprasidone for agitation or psychosis in dementia: Four cases

International Journal of Psychiatry in Medicine

Volumn 35, Issue 1, 2005, Pages 91-98

  Cole, Steven A ^a   Saleem, Rehan ^b   Shea, William P ^c   Sedler, Mark ^a   Sablosky, Marilyn ^c   Jyringi, Darlene ^a   Smith, Angela ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b University of Connecticut Health Sciences Center ^*

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Agitation; Atypical antipsychotic medication; Dementia; Psychosis of dementia; Ziprasidone

Indexed keywords

CARBAMAZEPINE; ESCITALOPRAM; GABAPENTIN; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADULT; AGED; AGITATION; BEHAVIOR; CASE REPORT; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART DISEASE; HUMAN; MALE; PSYCHOSIS; QT INTERVAL; REVIEW; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; THIAZOLES;

EID: 23044500080     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/NAMG-XXGG-WDVY-GX04     Document Type: Review

References (18)

1. Weiden PJ, Iqbal N, Mendelowitz AJ, Tandon R, Zimbroff DL, Ross R. Best clinical practice with ziprasidone: Update after one year of experience. Journal of Psychiatric Practice Mar 2002;8(2):81-98.
2. Caley CF, Cooper CK. Ziprasidone: The fifth atypical antipsychotic. Annals of Pharmacotherapy 2002;36(5):839-851.
3. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. Journal of Clinical Psychiatry Jun 2002;63(6):513-515.
4. Currier GW, Trenton A. Pharmacological treatment of psychotic agitation. CNS Drugs 2002;6(4):219-228.
5. Schneider LLC, Davis K, et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CTIE). American Journal of Geriatric Psychiatry 2001;9:346-360.
6. Jeste DFS. Psychosis of Alzheimer's disease and related dementias. American Journal of Geriatric Psychiatry 2000;8:29-34.
7. Berkowitz A. Ziprasidone for dementia in elderly patients: Case review. Journal of Psychiatric Practice 2003;9(6):469-473.
8. Leso L, Schwartz TL. Ziprasidone treatment of delirium. Psychosomatics 2002; 43(1):61-62.
9. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16(1):23-45.
10. Wilner KD, Anziano RJ, Johnson AC, Miceli JJ, Fricke JR, Titus CK. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. Journal of Clinical Psychopharmacology 2002; 22(2):206-210.
11. Schmidt SWLL, Howard HR Jr, Zorn SH. Ziprasidone: A novel antipsychotic with a unique human receptor binding profile. European Journal of Pharmacology 2001; 425(3):197-201.
12. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62(11):1649-1671.
13. White MC. Antipsychotics and QTc interval prolongation. Connecticut Medicine 2002;66(8):461-463.
14. Piepho RW. Cardiovascular effects of antipsychotics used in bipolar illness. Journal of Clinical Psychiatry 2002;63(suppl4):20-23.
15. Glassman AH, Bigger JT Jr. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. American Journal of Psychiatry 2001;158(11):1774-1782.
16. Meltzer HY, Davidson M, Glassman AH, Vieweg WVR. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment. Journal of Clinical Psychiatry 2002;63(suppl9).
17. Morganroth J. Variability of the QTc interval: Impact on defining drug effect and low-frequency cardiac event. American Journal of Cardiology 1993;72:26B-31B.
18. Brook S, Lucey JV, Gunn KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Journal of Clinical Psychiatry 2000;61:933-941.